

Package leaflet: Information for the user

Derinik 0.18 mg tablets

Derinik 0.35 mg tablets

Derinik 0.7 mg tablets

pramipexole

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What {Product name} is and what it is used for
2. What you need to know before you take {Product name}
3. How to take {Product name}
4. Possible side effects
5. How to store {Product name}
6. Contents of the pack and other information

1. What {Product name} is and what it is used for

{Product name} contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.

{Product name} is used to:

- treat the symptoms of primary Parkinson's disease in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson's disease).
- treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.

2. What you need to know before you take {Product name}

Do not take {Product name}

- if you are allergic to pramipexole or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before taking {Product name}. Tell your doctor if you have (had) or develop any medical conditions or symptoms, especially any of the following:

- Kidney disease
- Hallucinations (seeing, hearing or feeling things that are not there). Most hallucinations are visual.
- Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs). If you have advanced Parkinson's disease and are also taking levodopa, you might develop dyskinesia during the up-titration of {Product name}.
- Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)). In particular, you may experience forward flexion of the head and neck (also called antecollis),

forward bending of the lower back (also called camptocormia) or sideways bending of the back (also called pleurothotonus or Pisa Syndrome). If this happens, your doctor may want to change your medication.

- Sleepiness and episodes of suddenly falling asleep.
- Psychosis (e.g. comparable with symptoms of schizophrenia).
- Vision impairment. You should have regular eye examinations during treatment with {Product name}.
- Severe heart or blood vessels disease. You will need to have your blood pressure checked regularly, especially at the beginning of treatment. This is to avoid postural hypotension (a fall in blood pressure on standing up).
- Restless legs augmentation syndrome. If you experience that symptoms start earlier than usual in the evening (or even the afternoon), are more intense or involve larger parts of the affected limbs or involve other limbs. Your doctor may lower your dose or stop the treatment.

Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings. Your doctor may need to adjust or stop your dose.

Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion or loss of reality). Your doctor may need to adjust or stop your dose.

Tell your doctor if you experience symptoms such as depression, apathy, anxiety, fatigue, sweating or pain after stopping or reducing your {Product name} treatment. If the problems persist more than a few weeks, your doctor may need to adjust your treatment.

Tell your doctor if you are developing an inability of keeping your body and neck straight and upright (axial dystonia). If this happens, your doctor may want to adjust or change your medication.

Children and adolescents

{Product name} is not recommended for use in children or adolescents under 18 years.

Other medicines and {Product name}

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

You should avoid taking {Product name} together with antipsychotic medicines.

Take care if you are taking the following medicines:

- cimetidine (to treat excess stomach acid and stomach ulcers);
- amantadine (which can be used to treat Parkinson's disease);
- mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia);
- zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system);
- cisplatin (to treat various types of cancers);
- quinine (which can be used for the prevention of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria));
- procainamide (to treat irregular heart beat).

If you are taking levodopa, the dose of levodopa is recommended to be reduced when you start treatment with {Product name}.

Take care if you are using any medicines that calm you down (have a sedative effect) or if you are drinking alcohol. In these cases {Product name} may affect your ability to drive and operate machinery.

{Product name} with food, drink and alcohol

You should be cautious while drinking alcohol during treatment with {Product name}.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will then discuss with you if you should continue to take {Product name}.

The effect of {Product name} on the unborn child is not known. Therefore, do not take {Product name} if you are pregnant unless your doctor tells you to do so.

{Product name} should not be used during breast-feeding. {Product name} can reduce the production of breast milk. Also, it can pass into the breast milk and can reach your baby. If use of {Product name} is unavoidable, breast-feeding should be stopped.

Driving and using machines

{Product name} can cause hallucinations (seeing, hearing or feeling things that are not there). If affected, do not drive or use machines.

{Product name} has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson's disease. If you experience these side effects, you must not drive or operate machinery. You should tell your doctor if this occurs.

3. How to take {Product name}

Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. Your doctor will advise you on the right dosing.

You can take {Product name} with or without food. Swallow the tablets with water.

Parkinson's disease

The daily dose is to be taken divided into 3 equal doses.

During the first week, the recommended dose is ½ tablet {Product name} 0.18 mg three times a day (equivalent to 0.264 mg daily):

	1st week
Number of tablets	½ tablet {Product name} 0.18 mg three times a day (equivalent to 0.088 mg three times a day)
Total daily dose (mg)	0.264

This will be increased every 5-7 days as directed by your doctor until your symptoms are controlled (maintenance dose).

	2nd week	3rd week
Number of tablets	1 tablet {Product name} 0.18 mg three times a day	1 tablet {Product name} 0.35 mg three times a day OR

		2 tablets {Product name} 0.18 mg three times a day
Total daily dose (mg)	0.54	1.1

The recommended maintenance dose is 1.1 mg per day. However, your dose may have to be increased even further. If necessary, your doctor may increase your tablet dose up to a maximum of 3.3 mg of pramipexole a day. A lower maintenance dose of 0.264 mg a day is also possible.

	Lowest maintenance dose	Highest maintenance dose
Number of tablets	½ tablet {Product name} 0.18 mg three times a day (equivalent to 0.088 mg three times a day)	1 tablet {Product name} 0.7 mg and 1 tablet {Product name} 0.35 mg three times a day
Total daily dose (mg)	0.264	3.15

Patients with kidney disease

If you have moderate or severe kidney disease, your doctor will prescribe a lower dose. In this case, you will have to take the tablets only once or twice a day. If you have moderate kidney disease, the recommended starting dose is ½ tablet {Product name} 0.18 mg twice a day. In severe kidney disease, the recommended starting dose is just ½ tablet {Product name} 0.18 mg a day.

Restless Legs Syndrome

The dose is usually taken once a day, in the evening, 2-3 hours before bedtime.

During the first week, the recommended dose is ½ tablet {Product name} 0.18 mg once a day (equivalent to 0.088 mg daily):

	1st week
Number of tablets	½ tablet {Product name} 0.18 mg (equivalent to 0.088 mg)
Total daily dose (mg)	0.088

This will be increased every 4 - 7 days as directed by your doctor until your symptoms are controlled (maintenance dose).

	2nd week	3rd week	4th week
Number of tablets	1 tablet {Product name} 0.18 mg	1 tablet {Product name} 0.35 mg OR 2 tablets {Product name} 0.18 mg	1 tablet {Product name} 0.35 mg and 1 tablet {Product name} 0.18 mg OR 3 tablets {Product name} 0.18 mg
Total daily dose (mg)	0.18	0.35	0.54

The daily dose should not exceed 3 tablets {Product name} 0.18 mg or a dose of 0.54 mg (0.75 mg pramipexole salt).

If you stop taking your tablets for more than a few days and want to restart the treatment, you must start again at the lowest dose. You can then build up the dose again, as you did the first time. Ask your doctor for advice.

Your doctor will review your treatment after 3 months to decide whether or not to continue the treatment.

Patients with kidney disease

If you have severe kidney disease, {Product name} may not be a suitable treatment for you.

For certain dosages, other more appropriate strengths may be available from other pramipexol products and could be prescribed by the doctor.

If you take more {Product name} than you should

If you accidentally take too many tablets,

- Contact your doctor or nearest hospital casualty department immediately for advice.
- You may experience vomiting, restlessness, or any of the side effects as described in section 4, "Possible side effects".

If you forget to take {Product name}

Do not worry. Simply leave out that dose completely and then take your next dose at the right time. Do not take a double dose to make up for a forgotten tablet.

If you stop taking {Product name}

Do not stop taking {Product name} without first talking to your doctor. If you have to stop taking this medicine, your doctor will reduce the dose gradually. This reduces the risk of worsening symptoms.

If you suffer from Parkinson's disease you should not stop treatment with {Product name} abruptly. A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk. The symptoms include:

- akinesia (loss of muscle movement),
- rigid muscles,
- fever,
- unstable blood pressure,
- tachycardia (increased heart rate),
- confusion,
- depressed level of consciousness (e.g. coma).

If you stop or reduce {Product name} you may also develop a medical condition called dopamine agonist withdrawal syndrome. The symptoms include depression, apathy, anxiety, fatigue, sweating or pain. **If you experience these symptoms you should contact your physician.**

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you suffer from **Parkinson's disease**, you may experience the following side effects:

Very common (may affect more than 1 in 10 people):

- Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)
- Sleepiness
- Dizziness
- Nausea (sickness)

Common (may affect up to 1 in 10 people):

- Urge to behave in an unusual way
- Hallucinations (seeing, hearing or feeling things that are not there)
- Confusion
- Tiredness (fatigue)

- Sleeplessness (insomnia)
- Excess of fluid, usually in the legs (peripheral oedema)
- Headache
- Hypotension (low blood pressure)
- Abnormal dreams
- Constipation
- Visual impairment
- Vomiting (being sick)
- Weight loss including decreased appetite

Uncommon (may affect up to 1 in 100 people):

- Paranoia (e.g. excessive fear for one's own well-being)
- Delusion
- Excessive daytime sleepiness and suddenly falling asleep
- Amnesia (memory disturbance)
- Hyperkinesia (increased movements and inability to keep still)
- Weight increase
- Allergic reactions (e.g. rash, itching, hypersensitivity)
- Fainting
- Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)*
- Inappropriate antidiuretic hormone secretion*
- Restlessness
- Dyspnoea (difficulties to breathe)
- Hiccups
- Pneumonia (infection of the lungs)
- Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
 - Strong impulse to gamble excessively despite serious personal or family consequences.
 - Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.
 - Uncontrollable excessive shopping or spending
 - Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*
- Delirium (decreased awareness, confusion, loss of reality)

Rare (may affect up to 1 in 1,000 people):

- Mania (agitation, feeling elated or over-excited)
- Spontaneous penile erection

Not known (frequency cannot be estimated from the available data):

- After stopping or reducing your {Product name} treatment: Depression, apathy, anxiety, fatigue, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).

Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.

For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 2,762 patients treated with pramipexole. The frequency category is probably not greater than “uncommon”.

If you suffer from **Restless Legs Syndrome**, you may experience the following side effects:

Very common (may affect more than 1 in 10 people):

- Symptoms that start earlier than usual, are more intense or involve other limbs (Restless legs augmentation syndrome)
- Nausea (sickness)

Common (may affect up to 1 in 10 people):

- Changes in sleep pattern, such as sleeplessness (insomnia) and sleepiness
- Tiredness (fatigue)
- Headache
- Abnormal dreams
- Constipation
- Dizziness
- Vomiting (being sick)

Uncommon (may affect up to 1 in 100 people):

- Urge to behave in an unusual way*
- Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)*
- Inappropriate antidiuretic hormone secretion*
- Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)
- Hyperkinesia (increased movements and inability to keep still)*
- Paranoia (e.g. excessive fear for one's own well-being)*
- Delusion*
- Amnesia (memory disturbance)*
- Hallucinations (seeing, hearing or feeling things that are not there)
- Confusion
- Excessive daytime sleepiness and suddenly falling asleep
- Weight increase
- Hypotension (low blood pressure)
- Excess of fluid, usually in the legs (peripheral oedema)
- Allergic reactions (e.g. rash, itching, hypersensitivity)
- Fainting
- Restlessness
- Visual impairment
- Weight loss including decreased appetite
- Dyspnoea (difficulties to breathe)
- Hiccups
- Pneumonia (infection of the lungs)*
- Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
 - Strong impulse to gamble excessively despite serious personal or family consequences*
 - Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive*
 - Uncontrollable excessive shopping or spending*
 - Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*
- Mania (agitation, feeling elated or over-excited)*
- Delirium (decreased awareness, confusion, loss of reality)*

Rare (may affect up to 1 in 1,000 people):

- Spontaneous penile erection

Not known (frequency cannot be estimated from the available data):

- After stopping or reducing your {Product name} treatment: Depression, apathy, anxiety, fatigue, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).

Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms

For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 1,395 patients treated with pramipexole. The frequency category is probably not greater than “uncommon”.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system listed in Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store {Product name}

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What {Product name} contains

- The active substance is pramipexole.
Each {Product name} 0.18 mg tablet contains 0.18 mg pramipexole (as 0.25 mg pramipexole dihydrochloride monohydrate).
Each {Product name} 0.35 mg tablet contains 0.35 mg pramipexole (as 0.5 mg pramipexole dihydrochloride monohydrate).
Each {Product name} 0.7 mg tablet contains 0.7 mg pramipexole (as 1.0 mg pramipexole dihydrochloride monohydrate).
- The other ingredients are Starch, pregelatinised (Starch maize 1500), Mannitol, Cellulose, microcrystalline, Povidone (27.0-32.4), Talc and Magnesium stearate.

What {Product name} looks like and contents of the pack

{Product name} 0.18 mg:

White, round tablets, marked on one side with a “1” (one), scored on the other side with no defects and dimensions 6.0 ±0.1 mm in diameter and 3.0 mm ±0.2 mm in thickness

The tablets can be divided into equal doses.

{Product name} 0.35 mg:

White, round tablets, marked on one side with a “2” (two), scored on the other side with no defects and dimensions 6.0 ±0.1 mm in diameter and 3.0 mm ±0.2 mm in thickness

The tablets can be divided into equal doses.

{Product name} 0.70 mg:

White, round tablets, marked on one side with a “3” (three), scored on the other side with no defects and dimensions 6.0 ±0.1 mm in diameter and 3.0 mm ±0.2 mm in thickness

The tablets can be divided into equal doses.

{Product name} is available in aluminium/aluminium blister strips of 10 tablets per strip, in cartons containing 3 or 10 blister strips (30 or 100 tablets).

Not all pack sizes may be marketed.

Marketing Authorisation Holder

[To be completed nationally]

Manufacturer

Pharmathen S.A., Dervenakion 6, 15351, Pallini, Attiki , Greece

This leaflet was last revised in {MM/YYYY}.

[To be completed nationally]16 December 2024